quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:45:00·42d
PRRelease
Celularity Inc. logo
NexGel Inc logo

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

CELU· Celularity Inc.NXGL· NexGel Inc
Health Care
Original source

Companies

  • CELU
    Celularity Inc.
    Health Care
  • NXGL
    NexGel Inc
    Health Care

Recent analyst ratings

  • Jan 30CELUUpdateMorgan Stanley$1.00
  • Dec 22CELUUpdateOppenheimer-
  • Jun 22CELUUpdateH.C. Wainwright$15.00
  • Apr 6CELUUpdateTruist$10.00
  • Feb 25NXGLUpdateMaxim Group$6.00
  • Jan 28CELUUpdateOppenheimer$9.00

Related

  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.
  • SEC2d
    NexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
  • SEC2d
    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Leadership Update, Other Events, Financial Statements and Exhibits
  • PR2d
    NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
  • PR2d
    Celularity Announces Closing of Transaction with NexGel
  • PR6d
    Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
  • PR6d
    NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
  • INSIDER8d
    SEC Form 4 filed by Hariri Robert J
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022